Allergopharma

What Allergopharma does

Allergopharma GmbH & Co. KG is a German pharmaceutical company founded in 1969, specializing in the diagnosis and treatment of IgE-mediated allergic diseases. It operates as a wholly-owned subsidiary of Dermapharm AG within the Dermapharm Unternehmensgruppe, alongside other pharmaceutical entities including acis, Arkopharma, axicorp pharma, mibe arzneimittel, strathmann, and Trommsdorff. The company's core technology is allergen immunotherapy (AIT), a causal treatment approach targeting pollen, house dust mites, and animal allergies, complemented by symptomatic therapy solutions for acute relief and accompanying medication.

Allergopharma's product portfolio is organized into two lines: Allergen-Immuntherapie (AIT) products that provide sustainable symptom relief, and symptomatic therapies for acute or adjunctive use. All products are manufactured in Germany to high quality standards. Distribution is concentrated in the DACH region (Germany, Austria, Switzerland), with localized country-specific websites. The company reaches medical professionals through a DocCheck-authenticated Fachkreise portal and a structured medical education program (QuartRunde webinars, allergoFresh practical training, allergoDirekt topical sessions). Patients are served via the allergie-freizeit.de portal, which provides allergy information, treatment guidance, and lifestyle resources.

The business model is built on B2B pharmaceutical product sales through professional healthcare networks and pharmacy distribution, supplemented by direct-to-patient content and services. Revenue is not publicly disclosed, and Allergopharma does not operate as an independent public entity. Customer segments are bifurcated into medical professionals (allergologists, physicians) and patients, with dedicated channels serving each. Marketing activity spans LinkedIn, Xing, a Mediathek video library, and live educational events. The company does not disclose pricing publicly, and product-specific information requires authenticated portal access.

Name

Allergopharma

Legal name

Allergopharma GmbH & Co. KG

Website

https://allergopharma.com

Company type

Private

Founded year

1969

Operating status

Operating

Short description

Allergopharma GmbH & Co. KG is a German pharmaceutical subsidiary of Dermapharm AG that develops and distributes allergen immunotherapy and symptomatic therapy products for pollen, house dust mite, and pet allergies across DACH markets.

Ownership category

akta.pro rank

Product category

Allergy Pharmaceuticals / Allergen Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF), Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC), Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)

Keywords

• Allergen immunotherapy
• Allergy pharmaceuticals
• Allergy diagnostics
• Symptomatic allergy therapy
• IgE-mediated allergy treatment

Headquarters

HQ city

Reinbek

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Allergopharma generates revenue through the sale of allergy diagnostic and therapeutic pharmaceutical products, including both causal treatments (allergen immunotherapy) and symptomatic therapy solutions for acute allergy treatment and accompanying medication.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Allergopharma manufactures and sells pharmaceutical products for allergy diagnosis and treatment. Its core offerings are Allergen-Immuntherapie (AIT) products that provide causal treatment of IgE-mediated allergic diseases (pollen, house dust mite, and animal allergies) for sustainable symptom relief, complemented by symptomatic therapy solutions for acute allergy treatment and accompanying medication. Products are manufactured in Germany to highest quality standards and are sold through professional healthcare channels and pharmacies across the DACH region.

Product overview

Allergopharma offers a dual-product portfolio focused on allergy diagnosis and treatment. The core offering consists of Allergen-Immuntherapie (AIT) products for causal treatment of IgE-mediated allergic diseases, addressing pollen, house dust mite, and animal allergies. This is complemented by symptomatic therapy solutions for acute allergy symptom relief and accompanying medication. All products are manufactured in Germany to highest quality standards and are distributed through portals for both medical professionals (Fachkreise) and patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Allergen-Immuntherapie (AIT) Produkte Pharmaceutical allergen immunotherapy products providing causal treatment of IgE-mediated allergic diseases, including therapies for pollen, house dust mite, and animal allergies. They enable sustainable relief from allergy symptoms and are prescribed and administered by allergologists and physicians to patients with IgE-mediated allergies.
• Symptomatische Therapie-Lösungen Symptomatic therapy pharmaceutical solutions used as accompanying medication or for the acute treatment of allergy symptoms, providing complementary care alongside causal allergen immunotherapy treatments for patients with pollen, house dust mite, and animal allergies.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Dermapharm AG (Parent Company)coreOthersAllergopharma GmbH & Co. KG is a wholly-owned subsidiary of Dermapharm AG, part of the Dermapharm Unternehmensgruppe. The group includes multiple pharmaceutical companies including acis, Arkopharma, axicorp pharma, candoro ethics, huebner vital, mibe arzneimittel, mibetec, strathmann, and Trommsdorff.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• ALK-Abelló: Danish global leader in allergy immunotherapy (AIT), manufacturing SCIT and SLIT products for pollen, dust mite, and venom allergies. Most direct competitor to Allergopharma in allergen-specific immunotherapy, competing head-to-head in European markets and globally.
• Allergy Therapeutics: UK-based specialty pharmaceutical company developing and commercializing allergy vaccines and diagnostics, with strong European footprint. Comparable to Allergopharma in its specialized focus on subcutaneous and sublingual AIT for pollen and venom allergies.
• LETI Pharma: Spanish pharmaceutical company specializing in allergen immunotherapy and diagnostics for respiratory allergies, with strong presence in Spanish and Latin American markets. Comparable to Allergopharma in its focused AIT product portfolio and European specialist positioning.
• Stallergenes Greer: France-based global AIT specialist offering a broad portfolio of subcutaneous and sublingual allergen immunotherapy products. Direct competitor to Allergopharma in causal treatment of IgE-mediated respiratory allergies, particularly across European markets.
• HAL Allergy: Dutch-headquartered AIT specialist offering diagnostic allergens and immunotherapy products for respiratory and insect venom allergies across Europe. Comparable to Allergopharma as a mid-sized European specialist focused on allergen extracts and immunotherapy.
• Roxall Medizin: German AIT specialist marketing allergen immunotherapy products in German-speaking markets. Most direct DACH market competitor to Allergopharma, sharing the same physician (allergologist) customer base.
• Bencard Allergie: German allergy therapeutics company offering diagnostic allergens and immunotherapy products, part of the Allergy Therapeutics group. Comparable to Allergopharma as a DACH-focused AIT specialist serving allergologists and patients.

Broad incumbents

• Dermapharm AG: German publicly-listed pharmaceutical group and parent company of Allergopharma, operating a diversified portfolio across branded pharmaceuticals, cosmetics, and consumer health. Relevant as parent and comparable incumbent in German pharmaceutical manufacturing and distribution.
• Sanofi: Global pharmaceutical company with a respiratory and allergy portfolio (e.g., allergy immunotherapy franchises historically, plus adjacent biologics). Overlaps with Allergopharma's therapeutic area at a much broader scale across geographies and product types.
• Thermo Fisher Scientific (Phadia): Global leader in allergy diagnostics through its Phadia platform (ImmunoCAP), serving the same allergology customer base as Allergopharma. Comparable in serving allergy diagnosis workflows but at broader scale and in diagnostics rather than therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/allergopharma-j.-ganzer-kg-pharmazeutische-erzeugnisse

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allergopharma